Alpha Tau Medical (DRTS) Return on Equity (2022)

Alpha Tau Medical's (DRTS) quarterly Return on Equity came in at 0.0% in Q4 2022, little changed quarter-over-quarter from 0.0% in Q3 2022.

Alpha Tau Medical (DRTS) Return on Equity (2022) Analysis & Trends

Alpha Tau Medical has disclosed Return on Equity across 1 years of filings, most recently posting 0.0% for Q4 2022.

Return on Equity for Q4 2022 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was 0.0% (changed N/A YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
Return on Equity came in at 0.0% for Q4 2022 at Alpha Tau Medical, roughly flat from 0.0% in the prior quarter.
In the past five years, Return on Equity ranged from a high of 0.01% in Q1 2022 to a low of 0.0% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROE (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-0.81%
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-0.04%
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	0.00%
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-0.01%
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	0.00%
9	Abivax	94.37 Bn	94.37 Bn	-	-0.01%
10	Alpha Tau Medical	2,416.70	-76.42 Mn	-	-

Download Data